Inspection Backlogs Post-COVID 2025
In the wake of COVID-19, global regulators are still working through substantial backlogs in pharmaceutical manufacturing site inspections. For the industry, these delays add uncertainty to supply chain planning, maintaining compliance, and anticipating regulatory measures.
Ireland in Focus: 15% U.S. Tariffs Challenge Pharma Exports
Ireland has become the backbone of transatlantic medicine flows. The 15% U.S. tariff on EU pharmaceutical imports (White House Fact Sheet, July 28, 2025), effective August, ends decades of tariff-free medicine trade and adds new uncertainty. With Ireland producing APIs and finished drugs across immunology, oncology, and GLP-1 therapies, the stakes are high for U.S. […]
GLP-1 Market Overview 2025
Amid rapid market growth, this report offers unique insights into the evolving GLP-1 supply landscape, drawing on QYOBO’s unmatched visibility into global manufacturing sites, regulatory activity, and price trends. It outlines the shift from current Europe-based manufacturing toward increasing reliance on Chinese and Indian suppliers in future supply chains. The report also examines infrastructure investments, API costs, and site-level compliance at GLP-1 manufacturing facilities, providing strategic guidance for decision makers across the pharmaceutical industry.
API Market: Trends in Drug Master Filings Across the U.S., Europe, Japan, and China in 2025
QYOBO’s first-of-its-kind comparison of API Drug Master Filings across the U.S., Europe, Japan, and China, powered by its unique mapping of 15,000 manufacturing sites worldwide, offers insights into geographic trends and leading players in the global API landscape.
How Tariff Uncertainty Is Reshaping U.S. Pharma Supply Chains
The U.S. government’s 2025 tariff policy marks a major shift by introducing a 20% tariff on pharmaceuticals imported from China, products that were previously exempt under the WTO Pharmaceutical Agreement. Additional tariffs targeting imports from the EU and India are under consideration as of April 2025.
QYOBO is closely tracking these developments. Leveraging data from the QYOBO platform, we analyze the potential implications of the new tariff regime on U.S. pharmaceutical supply security, global supply chain dynamics, and strategic risks and opportunities for pharmaceutical companies.
Tariffs could lead to higher drug prices, supply disruptions, and manufacturing shifts. However, generics manufacturers may face greater challenges adapting due to cost constraints and limited margins.
Big-Data-Driven M&A in Pharma: The Competitive Edge of Site-level Intelligence
Private equity investments are transforming the pharmaceutical manufacturing sector, unlocking new opportunities amid shifting global market dynamics. With over 1,900 manufacturing sites across Europe, strategic acquisitions require data-driven insights to navigate compliance risks, ownership complexities, and supply chain dependencies. Discover how advanced analytics platforms empower investors to make informed M&A decisions and gain a competitive edge in this evolving landscape.
U.S. Pharmaceutical Supply in the Context of Recent Tariff Plans
The U.S. government’s 2025 tariff policy marks a major shift by introducing a 20% tariff on pharmaceuticals imported from China, products that were previously exempt under the WTO Pharmaceutical Agreement. Additional tariffs targeting imports from the EU and India are under consideration as of April 2025.
QYOBO is closely tracking these developments. Leveraging data from the QYOBO platform, we analyze the potential implications of the new tariff regime on U.S. pharmaceutical supply security, global supply chain dynamics, and strategic risks and opportunities for pharmaceutical companies.
Tariffs could lead to higher drug prices, supply disruptions, and manufacturing shifts. However, generics manufacturers may face greater challenges adapting due to cost constraints and limited margins.
QYOBO API1000 Price Index – 64% of Prices Dropped in 2024
Amid ongoing shifts in the global pharmaceutical market — including increasing regulatory scrutiny, raw material shortages, and evolving geopolitical tensions — the industry continues to navigate a landscape of uncertainty. In 2024, global API prices have largely trended downward, with QYOBO’s platform tracking these changes for thousands of APIs, excipients, intermediates and chemicals. This analysis describes API price fluctuations, highlights shifts across therapeutic categories, and provides AI-driven price forecasts for the coming months.
API Market: 5-Year Trends in USDMF and CEP Approvals
The API market is evolving rapidly, with regulatory approvals on the rise and manufacturing shifting towards Asia. Over the past five years, USDMF and CEP approvals have grown significantly, reflecting increasing demand for APIs in key therapeutic areas. India and China have emerged as dominant players, reshaping the industry landscape. What do these trends mean for the future of pharmaceutical manufacturing? Explore our latest insights.
FDA Drug Approvals: Key Trends, Leading Companies and Innovation Hubs
FDA drug approvals serve as the pulse of pharmaceutical innovation. Between 2015 and 2024, the FDA approved 462 new drugs – a 69% increase from the previous decade. However, annual growth has slowed, indicating that investments in drug development are outpacing new approvals.
